The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes

Table 2

Uni- and multivariate Cox regression analysis of biochemical recurrence (BCR) free survival and overall survival (OS) of the continuous PDE4D7 scores. In multivariate analysis, the PDE4D7 scores were adjusted by presurgical clinical variables or the CAPRA score as indicated. Biopsy Gleason and pathology stage were modeled as categories. All other demographic and clinical variables as well as the PDE4D7 scores were modeled as continuous variables. All variables were entered into the multivariate modeling. (a) Uni- and multivariate Cox regression analysis of the biochemical recurrence (BCR) free survival of the PDE4D7 score in the RP study cohort (n=503; 148 (29.4%) events); multivariate analysis was adjusted for presurgical variables or CAPRA scores. (b) Uni- and multivariate Cox regression analysis of the biochemical recurrence (BCR) free survival of the PDE4D7 score in the DB study cohort (n=151; 55 (36.4%) events); multivariate analysis was adjusted for presurgical variables or CAPRA scores. PDE4D7 score categories were defined as PDE4D7 (1-2): PDE4D7 scores (1 to <2); PDE4D7 (2-3): PDE4D7 scores (2 to <3); PDE4D7 (3-4): PDE4D7 scores (3 to <4); PDE4D7 (4-5): PDE4D7 scores (4 to <=5).

(a)

Pre-Surgical Clinical Parameters	univariate			multivariate
Endpoint BCR (#148/#503; 29.4)	p value	HR	95 CI of HR	p value	HR	95 CI of HR
Age at surgery	0,88	1,0	0.97 -1.03	0,77	1,00	0.96 to 1.02
Preoperative PSA	0,0002	1,03	1.01-1.04	0,00	1,08	1.03 to 1.1
PSA density	0,0100	2,15	1.2 to 3.8	0,03	0,12	0.02 to 0.8
Biopsy Gleason Score 3+3 (N=316); reference
Biopsy Gleason Score 3+4 (N=149)	0,0003	1,9	1.4-2.8	0,02	1,56	1.06 to 2.3
Biopsy Gleason Score >=4+3 (N=38)	<0.0001	6,2	3.9-9.7	<0.0001	4,82	2.9 to 7.9
Percentage Positive Biopsy Cores	<0.0001	4,2	2.3-7.7	0,08	2,29	0.91 to 5.7
Percentage Tumor in Biopsy	<0.0001	1,0	1.02-1.04	0,00	1,02	1.01 to 1.04
Clinical stage cT1c (N= 342); reference
Clinical stages cT2 & cT3 (N=161)	<0.0001	2,1	1.5 to 2.9	0,20	1,27	0.88 to 1.8
PDE4D7 (continuous)	<0.0001	0,53	0.41 to 0.67	<0.0001	0,52	0.4 to 0.68
Pre-Surgical Clinical Parameters	univariate			multivariate
Endpoint BCR (#148/#503; 29.4)	p value	HR	95 CI of HR	p value	HR	95 CI of HR
CAPRA Score	<0.0001	1,5	1.3 to 1.6	<0.0001	1,7	1.5 to 1.9
PDE4D7 (continuous)	<0.0001	0,47	0.33 to 0.65	<0.0001	0,56	0.43 to 0.72

(b)

Pre-Surgical Clinical Parameters	univariate			multivariate
Endpoint BCR (#55/#151; 36.4)	p value	HR	95 CI of HR	p value	HR	95 CI of HR
Age at surgery	0,81	0,99	0.95 to 1.04	0,006	0,94	0.89 to 0.98
Preoperative PSA	0,0001	1,04	1.02 to 1.06	0,002	1,1	1.03 to 1.2
PSA Density	0,003	2,7	1.4 to 5.3	0,18	0,26	0.04 to 1.9
Biopsy Gleason GG1 (n=85); reference
Biopsy Gleason GG2 (n=44)	0,07	1,9	0.95 to 3.8	0,10	1,9	0.89 to 3.9
Biopsy Gleason GG3 (n=20)	0,0001	4,3	2.04 to 9.2	0,02	2,6	1.2 to 5.7
Biopsy Gleason GG4 (n=7)	0,0007	5,7	2.1 to 15.8	0,01	4,1	1.4 to 11.6
Biopsy Gleason GG5 (n=11)	<0.0001	8,0	3.5 to 18.4	0,03	2,9	1.1 to 7.6
Percentage Positive Biopsy Cores	0,013	4,6	1.4 to 15.2	0,19	2,4	0.63 to 9.4
Clinical stage cT2 (n= 108); reference
Clinical stage cT3 (n=60)	0,007	2,0	1.2 to 3.4	0,05	1,7	0.99 to 3.1
PDE4D7 (continuous)	<0.0001	0,47	0.33 to 0.65	<0.0001	0,43	0.29 to 0.63
Pre-Surgical Clinical Parameters	univariate			multivariate
Endpoint BCR (#55/#151; 36.4)	p value	HR	95 CI of HR	p value	HR	95 CI of HR
CAPRA Score	<0.0001	1,5	1.3 to 1.6	<0.0001	1,4	1.2 to 1.6
PDE4D7 (continuous)	<0.0001	0,47	0.33 to 0.65	0,0001	0,53	0.38 to 0.74